Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., Lindberg, H., Morris, D., Nolè, F., Staffurth, J., Redfern, C., Sáez, M. I., Abida, W., Daugaard, G., Heidenreich, A., ... TRITON3 Investigators. (23 February 2023). Rucaparib or Physician's Choice in Metastatic Prostate Cancer. New England Journal of Medicine, 388 (8), 719 - 732. doi:10.1056/NEJMoa2214676 Peer Reviewed verified by ORBi |
Denis, C., COUSIN, F., De Laere, B., HUSTINX, R., SAUTOIS, B.* , & WITHOFS, N.*. (21 April 2022). Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice. Journal of Nuclear Medicine, 63 (12), 1815-1821. doi:10.2967/jnumed.121.263611 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Sautois, B., Loehr, A., Watkins, S. P., SCHROEDER, H., & Abida, W. (2022). A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration. Current Oncology, 29 (6), 4178-4184. doi:10.3390/curroncol29060333 Peer Reviewed verified by ORBi |
Martin, M., & SAUTOIS, B. (January 2021). Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene [letter to the editor]. Oral Oncology, 112, 104989. doi:10.1016/j.oraloncology.2020.104989 Peer Reviewed verified by ORBi |
Abida, W., Campbell, D., Patnaik, A., Shapiro, J. D., Sautois, B., Vogelzang, N. J., Voog, E. G., Bryce, A. H., McDermott, R., Ricci, F., Rowe, J., Zhang, J., Piulats, J. M., Fizazi, K., Merseburger, A. S., Higano, C. S., Krieger, L. E., Ryan, C. J., Feng, F. Y., ... Chowdhury, S. (2020). Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study. Clinical cancer research : an official journal of the American Association for Cancer Research, 26 (11), 2487-2496. doi:10.1158/1078-0432.CCR-20-0394 Peer reviewed |
Wick, M., Sautois, B., Freres, P., Denis, C., Seidel, L., Waltregny, D., & Gennigens, C. (2024). Metastatic reanl cell carcinoma : monocentric retrospective data on first-line treatment. Belgian Journal of Medical Oncology. Peer Reviewed verified by ORBi |
Denis, C., & Sautois, B. (November 2023). Mise au point et stratégies thérapeutiques dans le cancer de la prostate avancé et métastatique. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 47 (6), 300 - 308. doi:10.1016/j.mednuc.2023.09.003 Editorial reviewed |
Abida, W., Campbell, D., Patnaik, A., Bryce, A. H., Shapiro, J., Bambury, R. M., Zhang, J., Burke, J. M., Castellano, D., Font, A., Ganju, V., Hardy-Bessard, A.-C., McDermott, R., Sautois, B., Spaeth, D., Voog, E., Piulats, J. M., Pintus, E., Ryan, C. J., ... Chowdhury, S. (03 June 2023). Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. European Urology, 84 (3), 321-330. doi:10.1016/j.eururo.2023.05.021 Peer Reviewed verified by ORBi |
Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., Lindberg, H., Morris, D., Nolè, F., Staffurth, J., Redfern, C., Sáez, M. I., Abida, W., Daugaard, G., Heidenreich, A., ... TRITON3 Investigators. (23 February 2023). Rucaparib or Physician's Choice in Metastatic Prostate Cancer. New England Journal of Medicine, 388 (8), 719 - 732. doi:10.1056/NEJMoa2214676 Peer Reviewed verified by ORBi |
Loehr, A., Hussain, A., Patnaik, A., Bryce, A. H., Castellano, D., Font, A., Shapiro, J., Zhang, J., Sautois, B., Vogelzang, N. J., Chatta, G., Courtney, K., Harzstark, A., Ricci, F., Despain, D., Watkins, S., King, C., Nguyen, M., Simmons, A. D., ... Abida, W. (2023). Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. European Urology, 83 (3), 200-209. doi:10.1016/j.eururo.2022.09.010 Peer Reviewed verified by ORBi |
Verdonck Beatove, E., Piette, C., Sautois, B., & Gennigens, C. (2023). Late metastatic relapse of an initially bifocal intracranial germ cell tumor with modestly elevated tumor markers: A case report [Poster presentation]. 25th BSMO Annual Meeting 2023, Hasselt, Belgium. Peer reviewed |
Denis, C., COUSIN, F., De Laere, B., HUSTINX, R., SAUTOIS, B.* , & WITHOFS, N.*. (21 April 2022). Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice. Journal of Nuclear Medicine, 63 (12), 1815-1821. doi:10.2967/jnumed.121.263611 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Sautois, B., & Denis, C. (2022). Le médicament du mois : Apalutamide, Erleada® (2022). Revue Médicale de Liège, 77 (10), 609-615. Editorial Reviewed verified by ORBi |
Sautois, B., Loehr, A., Watkins, S. P., SCHROEDER, H., & Abida, W. (2022). A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration. Current Oncology, 29 (6), 4178-4184. doi:10.3390/curroncol29060333 Peer Reviewed verified by ORBi |
Denis, C., Cousin, F., De Laere, B., Hustinx, R., Sautois, B., & Withofs, N. (2022). Using 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer : an application of EAU/EANM recommendations in clinical practice [Poster presentation]. BMUC, Belgium. Editorial reviewed |
ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., ... Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571 Peer reviewed |
Colassin, A., Denis, C., HERMESSE, J., WALTREGNY, D., & SAUTOIS, B. (May 2021). Prise en charge d'un cancer de la prostate métastatique au diagnostic. Revue Médicale de Liège, 76 (5-6), 496-501. Peer reviewed |
Loehr, A., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., Zhang, J., Piulats, J. M., Hussain, A., Ryan, C. J., Merseburger, A. S., Daugaard, G., Heidenreich, A., Fizazi, K., Higano, C. S., ... Abida, W. (2021). Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clinical Cancer Research, 27 (24), 6677-6686. doi:10.1158/1078-0432.CCR-21-2199 Peer Reviewed verified by ORBi |
Martinez Chanza, N., Soukane, L., Barthelemy, P., Carnot, A., Gil, T., Casert, V., Vanhaudenarde, V., Sautois, B., Staudacher, L., Van den Brande, J., Culine, S., Seront, E., Gizzi, M., Albisinni, S., Tricard, T., Fantoni, J. C., Paesmans, M., Caparica, R., Roumeguere, T., & Awada, A. (2021). Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial). BMC Cancer, 21 (1), 1292. doi:10.1186/s12885-021-08990-3 Peer Reviewed verified by ORBi |
Lecocq, M., Poncin, A., & Sautois, B. (2021). Place de l’immunothérapie dans le traitement des carcinomes épidermoïdes de la tête et du cou. Revue Médicale de Liège, 76 (5-6), 398-402. Peer reviewed |
Denis, C., Sakalihasan, S., FRERES, P., WITHOFS, N., & SAUTOIS, B. (2021). Cemiplimab for cisplatin resistant metastatic penile cancer. Case Reports in Oncology, 14, 972-976. doi:10.1159/000517008 Peer Reviewed verified by ORBi |
Lambert, E., Hollebosch, S., van Praet, C., Van Bruwaene, S., Duck, L., De Roock, W., van Wambeke, S., Ghysel, C., Ameye, F., Schatteman, P., Vandenbroucke, F., Sautois, B., Baekelandt, F., Ost, D., Fransis, K., Filleul, B., Remondo, C., Wynendaele, W., Bamelis, B., ... Lumen, N. (2021). Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis. Acta Clinica Belgica, 1-9. doi:10.1080/17843286.2021.2001999 Peer Reviewed verified by ORBi |
Martin, M., & SAUTOIS, B. (January 2021). Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene [letter to the editor]. Oral Oncology, 112, 104989. doi:10.1016/j.oraloncology.2020.104989 Peer Reviewed verified by ORBi |
Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., Zhang, J., Piulats, J. M., Ryan, C. J., Merseburger, A. S., Daugaard, G., Heidenreich, A., Fizazi, K., Higano, C. S., Krieger, L. E., ... Chowdhury, S. A. (2020). Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. Journal of Clinical Oncology, 38 (32), 3763-3772. doi:10.1200/JCO.20.01035 Peer reviewed |
ONESTI, C. E., SCHROEDER, H., RORIVE, A., SAUTOIS, B., LECOCQ, M., Goffin, M., GONNE, E., COLLINGE, A., NICOLAERS, L., WERA, O., Catot, A., LOLY, C., PAULUS, A., SIBILLE, A., LOUSBERG, L., Troisfontaine, F., COLLIGNON, J., GENNIGENS, C., FRERES, P., & JERUSALEM, G. (2020). How do oncological patients perceive the Covid-19 (SARS-CoV-2) pandemic ? Experience from CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain. |
LECOCQ, M., ONESTI, C. E., SCHROEDER, H., RORIVE, A., Goffin, M., GONNE, E., SAUTOIS, B., Catot, A., WERA, O., NICOLAERS, L., COLLINGE, A., Collignon, J., FRERES, P., POLUS, M., DUYSINX, B., VAILLANT, F., GENNIGENS, C., MARCHAL, N., PONCIN, A., & JERUSALEM, G. (2020). Risk of SARS-CoV-2 infection and outcome after infection : Experience from the day-care unit at CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain. |
Abida, W., Campbell, D., Patnaik, A., Shapiro, J. D., Sautois, B., Vogelzang, N. J., Voog, E. G., Bryce, A. H., McDermott, R., Ricci, F., Rowe, J., Zhang, J., Piulats, J. M., Fizazi, K., Merseburger, A. S., Higano, C. S., Krieger, L. E., Ryan, C. J., Feng, F. Y., ... Chowdhury, S. (2020). Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study. Clinical cancer research : an official journal of the American Association for Cancer Research, 26 (11), 2487-2496. doi:10.1158/1078-0432.CCR-20-0394 Peer reviewed |
Hakenberg, O. W., Perez-Gracia, J. L., Castellano, D., Demkow, T., Ali, T., Caffo, O., Heidenreich, A., Schultze-Seemann, W., Sautois, B., Pavlik, I., Qin, A., Novosiadly, R. D., Shahir, A., Ilaria, R. J., & Nippgen, J. (2019). Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European journal of cancer (Oxford, England : 1990), 107, 186-195. doi:10.1016/j.ejca.2018.10.005 Peer reviewed |
SAUTOIS, B., SCHROEDER, H., MARTIN, M., PIRET, P., DEMEZ, P., BOUCHAIN, O., MUTIJIMA NZARAMBA, E., & MOREAU, P. (2016). Weekly cisplatin with radiotherapy for locally advanced head and neck squamous cell carcinoma. Journal of Balkan Union of Oncology, 21 (4), 979-988. Peer Reviewed verified by ORBi |
Machiels, J.-P. H., Van Maanen, A., Vandenbulcke, J.-M., Filleul, B., Seront, E., Henry, S., D'Hondt, L., Lonchay, C., Holbrechts, S., Boegner, P., Brohee, D., Dequanter, D., Louviaux, I., Sautois, B., Whenham, N., Berchem, G., Vanderschueren, B., Fontaine, C., Schmitz, S., ... Rottey, S. (2016). Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy. Oncologist, 21, 1-10. doi:10.1634/theoncologist.2016-0296 Peer Reviewed verified by ORBi |
Seront, E., Rottey, S., Filleul, B., Glorieux, P., Goeminne, J., Verschaeve, V., Vandenbulcke, J.-M., Sautois, B., Boegner, P., Gillain, A., van Maanen, A., & Machiels, J.-P. (2016). Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC). BJU International. doi:10.1111/bju.13415 Peer Reviewed verified by ORBi |
PIRET, P., WERENNE, X., Sautois, B., Demez, P., & Coucke, P. (2014). EXPLORATION ET TRAITEMENT D’UN CARCINOME EPIDERMOIDE GANGLIONNAIRE CERVICAL SANS PRIMITIF DECELE. Revue Médicale de Liège, 69 (Supp 1), 58-62. Peer reviewed |
Sautois, B., & GENNIGENS, C. (2013). Actualites therapeutiques dans le traitement medical du cancer de la prostate resistant a la castration. Revue Médicale de Liège, 68 (2), 94-6. Peer reviewed |
Seront, E., Rottey, S., Sautois, B., Kerger, J., D'Hondt, L. A., Verschaeve, V., Canon, J.-L., Dopchie, C., Vandenbulcke, J. M., Whenham, N., Goeminne, J. C., Clausse, M., Verhoeven, D., Glorieux, P., Branders, S., Dupont, P., Schoonjans, J., Feron, O., & Machiels, J.-P. (2012). Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Annals of Oncology, 23 (10), 2663-70. doi:10.1093/annonc/mds057 Peer Reviewed verified by ORBi |
PHAN BA, R., BELACHEW, S., JEDIDI, Z., SAUTOIS, B., DEPREZ, M., & MOONEN, G. (May 2011). Radiation-induced malignant peripheral nerve sheat tumors – a report of 2 cases [Poster presentation]. European Neurological Society 21st Meeting, Lisbon, Portugal. |
Martin, M., Demez, P., MOREAU, P., Devillers, D., PIRET, P., & Sautois, B. (January 2010). Chimiothérapie néoadjuvante dans les cancers "tête et cou". Revue Médicale de Liège, 65 (1), 15-17. Peer reviewed |
Gennigens, C., Sautois, B., & Jerusalem, G. (2010). Le medicament du mois. Everolimus (RAD001/Afinitor) dans le traitement du cancer du rein métastatique. Revue Médicale de Liège, 65 (4), 212-6. Peer reviewed |
Gennigens, C., Kridelka, F., Jerusalem, G., & Sautois, B. (2009). Ovariumkanker : nieuwe cytotoxica en ontwikkeling van gerichte therapieën. Gunaïkeia. Koninklijke Belgische Vereniging voor Gynecologie en Verloskunde, 14 (6), 174-190. Peer reviewed |
Gennigens, C., Collignon, J., Jerusalem, G., Rorive, A., & Sautois, B. (2009). Anticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites. Revue Médicale de Liège, 64 (5-6), 264-7. Peer reviewed |
Sautois, B., Martin, M., Demez, P., Piret, P., Devillers, D., & Moreau, P. (2009). Place des anticorps monoclonaux dans le traitement des tumeurs de la tete et du cou. Revue Médicale de Liège, 64 (5-6), 284-6. Peer reviewed |
Mievis, C., Jansen, N., Schleich, F., Gennigens, C., Rorive, A., Jerusalem, G., Fillet, G., & Sautois, B. (2009). Le cas clinique du mois. Reaction de rappel d'irradiation induite par l'administration de cyclophosphamide. Revue Médicale de Liège, 64 (4), 179-81. Peer reviewed |
Coucke, P., Piret, P., Werenne, X., Demez, P., Sautois, B., & Moreau, P. (2008). Les tumeurs de la sphere ORL: standards de traitement et nouvelles approches en radiothérapie. Revue Médicale de Liège, 63 (3), 141-8. Peer reviewed |
Paulus, A., Gennigens, C., Fillet, G., Loly, C., & Sautois, B. (September 2007). Traitement chimiothérapique actuel du cancer de l'ovaire. Revue Médicale de Liège, 62 (9), 539-47. Peer reviewed |
Gennigens, C., Sautois, B., Rorive, A., Fillet, G., & Jerusalem, G. (2007). Actualites therapeutiques en oncologie: l'essor des therapeutiques ciblees. Revue Médicale de Liège, 62 (5-6, May-Jun), 391-8. Peer reviewed |
Jerusalem, G., Rorive, A., Gennigens, C., Sautois, B., Mievis, C., & Fillet, G. (2007). Actualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des traitements cibles. Revue Médicale de Liège, 62 Spec No, 2-5. Peer reviewed |
Smeets, L., De Roover, A., & Sautois, B. (2006). Le cas clinique du mois. Recidive d'une tumeur testiculaire mixte 15 ans apres le traitement initial. Revue Médicale de Liège, 61 (10), 671-4. Peer reviewed |
Wauters, O., Sautois, B., & Fillet, G. (2005). L'image du mois. Une image de "lâcher de ballons" à l'imagerie thoracique. Revue Médicale de Liège, 60, 909. Peer reviewed |
Polus, M., Piront, P., Jerusalem, G., Sautois, B., Defechereux, T., de Leval, L., & Fillet, G. (February 2004). L'image du mois. Tumeur de Merkel : reponse majeure a la chimiotherapie. "Il n'y a pas que la neige qui fond au soleil". Revue Médicale de Liège, 59 (2), 67-8. Peer reviewed |
Gillain, S., Gennigens, C., Sautois, B., Polus, M., Bonnet, C., Fillet, G., & Jerusalem, G. (2004). Traitement du cancer du sein chez la personne âgée. Revue Médicale Suisse, 62, 1618-21. Peer Reviewed verified by ORBi |
Polus, M., Piront, P., Jerusalem, G., Sautois, B., Louis, E., Detroz, B., Laurent, S., Belaiche, J., & Fillet, G. (April 2003). Prevention primaire et secondaire du cancer colorectal. Revue Médicale de Liège, 58 (4), 247-53. Peer reviewed |
Baron, F., Frere, P., Baudoux, E., Sautois, B., Fillet, G., & Beguin, Y. (2003). Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. Haematologica, 88 (4), 478-80. Peer Reviewed verified by ORBi |
Hustinx, R., Sautois, B., Jerusalem, G., & Foidart, J. (2003). Radiothérapie métabolique des douleurs osseuses métastatiques. Médecine et Hygiène, 61, 1560-1564. Peer Reviewed verified by ORBi |
Pelerin, D., Silvestre, R. M., Jerusalem, G., Sautois, B., Polus, M., & Fillet, G. (December 2002). Comment je traite ... par hormonotherapie des patientes developpant des complications thrombo-emboliques lors du traitement d'un cancer du sein par tamoxifene. Revue Médicale de Liège, 57 (12), 755-6. Peer reviewed |
Polus, M., Honore, P., De Roover, A., Detry, O., Detroz, B., Jerusalem, G., Sautois, B., & Fillet, G. (December 2002). La carcinomatose hepatique du cancer colorectal: actualites therapeutiques. Revue Médicale de Liège, 57 (12), 771-8. Peer reviewed |
Polus, M., Bours, V., Jerusalem, G., Sautois, B., & Fillet, G. (July 2002). Comment je traite.... Le cancer avance du pancreas par une approche innovante dirigee contre les nouvelles cibles. Revue Médicale de Liège, 57 (7), 428-32. Peer reviewed |
Polus, M., Jerusalem, G., Sautois, B., Silvestre, R. M., & Fillet, G. (March 2002). Comment je traite.... Un cancer du pancreas avance. Revue Médicale de Liège, 57 (3), 131-4. Peer reviewed |
Polus, M., Jerusalem, G., Sautois, B., Silvestre, R. M., Collette, M. Y., Closon, M. T., & Fillet, G. (February 2002). Etude clinique du mois. Radio-chimiotherapie et chimiotherapie adjuvante apres resection a visee curative du cancer du pancreas: resultats de l'etude randomisee ESPAC-1. Revue Médicale de Liège, 57 (2), 119-22. Peer reviewed |
Baron, F., Sautois, B., Baudoux, E., Matus, G., Fillet, G., & Beguin, Y. (2002). Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 30 (6), 546-54. doi:10.1016/S0301-472X(02)00795-6 Peer reviewed |
SAUTOIS, B. (2002). Contribution à l'étude des greffes de cellules souches du sang périphérique [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/245949 |
Brasseur, E., Silvestre, R.-M., Jerusalem, G., Sautois, B., Polus, M., & Fillet, G. (2002). Prévention et traitement des nausées et vomissements après chimiothérapie anticancéreuse. Médecine et Hygiène, 60, 1509-1513. Peer Reviewed verified by ORBi |
Sylvestre, R.-M., Jerusalem, G., Sautois, B., Beguin, Y., & Fillet, G. (2001). Nouvelles approches thérapeutiques puor l'hypernéphrome métastasique. Médecine et Hygiène, 59, 1607-1609. Peer Reviewed verified by ORBi |
Sautois, B., Baudoux, E., Salmon, J., Michaux, S., Schaaf-Lafontaine, N., Pereira-Martins, M., Paulus, J.-M., Fillet, G., & Beguin, Y. (2001). Administration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation. Haematologica, 86 (11), 1209-18. Peer Reviewed verified by ORBi |
Jerusalem, G., Belhocine, T., Silvestre, R.-M., Sautois, B., Hustinx, R., Beguin, Y., Fillet, G., & Rigo, P. (2001). Place de la tomographie d'émission de positons dans le suivi thérapeutique du cancer du sein. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 25 (6), 341-346. Peer reviewed |
Scerbo, F., Matus, G., Sautois, B., & Fillet, G. (November 2000). Comment je traite ... le myelome multiple refractaire par thalidomide. Revue Médicale de Liège, 55 (11), 970-3. Peer reviewed |
Fraipont, V., Sautois, B., Baudoux, E., Pereira-Martins, M., Fassotte, M.-F., Hermanne, J. P., Jerusalem, G., Longree, L., Schaaf-Lafontaine, N., Fillet, G., & Beguin, Y. (2000). Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF. Transfusion, 40 (3), 339-47. doi:10.1046/j.1537-2995.2000.40030339.x Peer Reviewed verified by ORBi |
Sautois, B., Scerbo, F., Beguin, Y., & Fillet, G. (2000). Traitement des myélomes réfractaires par la Thalidomide. Médecine et Hygiène, 58, 1633-1634. Peer Reviewed verified by ORBi |
Sautois, B., Fraipont, V., Baudoux, E., Fassotte, M.-F., Hermanne, J. P., Jerusalem, G., Bours, V., Bosquee, L., Schaaf-Lafontaine, N., Paulus, J.-M., Sondag, D., Fillet, G., & Beguin, Y. (1999). Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica, 84 (4), 342-9. Peer Reviewed verified by ORBi |
Smitz, S., Neven, I., Sautois, B., & Tassin, F. (1999). L'image du mois. Purpura thrombocytopenique auto-immun. Revue Médicale de Liège, 54 (8), 645. Peer reviewed |
Beguin, Y., Baudoux, E., Sautois, B., Fraipont, V., Schaaf-Lafontaine, N., Pereira-Martins, M., Paulus, J.-M., Sondag, D., & Fillet, G. (1998). Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells. Transfusion, 38 (2), 199-208. doi:10.1046/j.1537-2995.1998.38298193106.x Peer Reviewed verified by ORBi |
Sautois, B., Fillet, G., & Beguin, Y. (1997). Comparative cytokine production by in vitro stimulated mononucleated cells from cord blood and adult blood. Experimental Hematology, 25 (2), 103-8. Peer reviewed |
Beguin, Y., Sautois, B., Forget, P., Bury, J., & Fillet, G. (1997). Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen. Cancer, 79 (7), 1351-4. doi:10.1002/(SICI)1097-0142(19970401)79:7<1351::AID-CNCR12>3.0.CO;2-Z Peer Reviewed verified by ORBi |
Beguin, Y., Grek, V., Weber, G., Sautois, B., Paquot, N., Pereira-Martins, M., Scheen, A., Lefèbvre, P., & Fillet, G. (1997). Acute Functional Iron Deficiency in Obese Subjects During a Very-Low-Energy All-Protein Diet. American Journal of Clinical Nutrition, 66 (1), 75-9. doi:10.1093/ajcn/66.1.75 Peer Reviewed verified by ORBi |
Beguin, Y., Loo, M., R'Zik, S., Sautois, B., Lejeune, F., Rorive, G., & Fillet, G. (1995). Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin. British Journal of Haematology, 89 (1), 17-23. doi:10.1111/j.1365-2141.1995.tb08916.x Peer Reviewed verified by ORBi |
Beguin, Y., Loo, M., R'Zik, S., Sautois, B., & Fillet, G. (1994). Significance of soluble transferrin receptor. Molecular Biology of Hematopoiesis, 451-464. |
Beguin, Y., Loo, M., R'Zik, S., Sautois, B., Lejeune, F., Rorive, G., & Fillet, G. (1994). Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: correlation of platelet count with erythropoietic activity and iron parameters. European Journal of Haematology, 53 (5), 265-70. doi:10.1111/j.1600-0609.1994.tb01318.x Peer Reviewed verified by ORBi |
Beguin, Y., Loo, M., R'Zik, S., Sautois, B., Lejeune, F., Rorive, G., & Fillet, G. (1993). Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood, 82 (7), 2010-6. doi:10.1182/blood.v82.7.2010.bloodjournal8272010 Peer Reviewed verified by ORBi |
Grek, V., BEGUIN, Y., Weber, G., Sautois, B., PAQUOT, N., SCHEEN, A., Lefebvre, P., & FILLET, G. (1992). Acute functional iron deficiency in obese subjects during very-low-energy all- protein diet [Poster presentation]. 24th Congress of The International Society of Haematology, London, United Kingdom. |
Beguin, Y., Sautois, B., & Fillet, G. (1991). Perspectives diagnostiques et thérapeutiques de l'érythropoïétine. Médecine et Hygiène, 49, 2034-2045. Peer Reviewed verified by ORBi |
Sautois, B., Mélon, P., Grek, V., Fassotte, M.-F., & Fillet, G. (1991). Thrombocytopénie allergique à la nitrofurantoïne. Revue Médicale de Liège, 46, 592. Peer reviewed |